Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Atsushi Shimizu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8307-2461; OpenAlex author ID A5027776738, A5126365267. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 13

  1. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  2. Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer. First author DOI 10.1002/jhbp.1436↗
  3. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00432-023-05594-1↗
  4. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2023.06.012↗
  5. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  6. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2018.12.015↗
  7. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12013↗
  8. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… First author DOI 10.1007/s00280-017-3250-8↗
  9. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11389↗
  10. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  11. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Co-author DOI 10.1097/mpa.0000000000000634↗
  12. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.109↗
  13. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/j.1349-7006.2012.02214.x↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuji Kitahata · 10 shared papers, 2012–2024 · strength 0.96
  2. Manabu Kawai · 10 shared papers, 2012–2024 · strength 0.96
  3. Hiroki Yamaue · 10 shared papers, 2012–2024 · strength 0.81
  4. Motoki Miyazawa · 9 shared papers, 2012–2024 · strength 0.75
  5. Ken‐ichi Okada · 8 shared papers, 2012–2024 · strength 0.71
  6. Seiko Hirono · 8 shared papers, 2012–2023 · strength 0.58
  7. Hideki Motobayashi · 3 shared papers, 2023–2024 · strength 0.54
  8. Tomohiro Yoshimura · 3 shared papers, 2023–2024 · strength 0.54
  9. Atsushi Miyamoto · 2 shared papers, 2023–2024 · strength 0.33
  10. Ken‐ichi Okada · 2 shared papers, 2014–2024 · strength 0.25
  11. Hiroshi Ishii · 2 shared papers, 2017–2026 · strength 0.24
  12. Naoto Egawa · 1 shared paper, 2026 · strength 0.18
  13. Masahiro Nakatochi · 1 shared paper, 2026 · strength 0.18
  14. Yasushi Adachi · 1 shared paper, 2026 · strength 0.18
  15. Satoshi Kobayashi · 1 shared paper, 2026 · strength 0.18
  16. Masato Ozaka · 1 shared paper, 2026 · strength 0.18
  17. Yuriko N. Koyanagi · 1 shared paper, 2026 · strength 0.18
  18. Norie Sawada · 1 shared paper, 2026 · strength 0.18
  19. Yingsong Lin · 1 shared paper, 2026 · strength 0.18
  20. Makoto Ueno · 1 shared paper, 2026 · strength 0.18
  21. Keitaro Matsuo · 1 shared paper, 2026 · strength 0.18
  22. Takuji Okusaka · 1 shared paper, 2026 · strength 0.18
  23. Shogo Kikuchi · 1 shared paper, 2026 · strength 0.18
  24. Naoki Sasahira · 1 shared paper, 2026 · strength 0.18
  25. Hiroaki Yanagimoto · 2 shared papers, 2016–2017 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.